The collaboration with UBC is focused on developing machine-learning based technology to improve the quality of our 3D printing.
Aspect is hosting a hands-on bioprinting session at the TERMIS-EU Workshop in Nantes, France, August 26-27.
The presentation will highlight milestone achievements to develop human liver tissue using Aspect’s microfluidic 3D bioprinting platform.
McMaster University will use the RX1 3D Bioprinter to investigate novel disease mechanisms for chronic lung diseases.
This $2.2M project is made possible by contributions from CQDM, CCS, Merck, GSK, Aspect Biosystems, and McGill University.
Aspect collaborates with the Center for Minimally Invasive Therapies (C-MIT) at the University of California, Los Angeles (UCLA).
Aspect will join 15 ventures from around the world in a multi-year collaboration to help align the future of work with social equity.
Aspect Biosystems Named 2019 Growth Stage Company of the Year by LifeSciences BC.
The National Research Council of Canada and Aspect Biosystems are collaborating to develop a 3D model of the blood-brain barrier.
Aspect is presenting preclinical data from recent studies focused on developing a bioprinted meniscus tissue for surgical implantation.
The Maastricht Institute for Technology-Inspired Regenerative Medicine will develop kidney tissue using an RX1™ Bioprinting Platform.
Government of Canada invests nearly $20M in top British Columbia companies in 2018.
BIOTECanada Gold Leaf Award Winner for Emerging Company of the Year 2018: Aspect Biosystems.
Spiro joins Aspect following his role as Biology Director at GlaxoSmithKline and as a Faculty Member at Northwestern University.
"Aspect Biosystems: Building a Global Discovery Ecosystem from Right Here in Canada" - BIOTECanada insights Magazine, Fall 2018
Aspect Biosystems announces collaboration with multinational JSR Corporation to develop human liver tissue.